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Abstract
Background: As supplement to KRAS mutational analysis, BRAF and PIK3CA mutations as well as expression of
PTEN may account for additional non-responders to anti-EGFR-MoAbs treatment. The aim of the present study was
to investigate the utility as biomarkers of these mutations in a uniform cohort of patients with metastatic colorectal
cancer treated with third-line cetuximab/irinotecan.
Methods: One-hundred-and-seven patients were prospectively included in the study. Mutational analyses of KRAS,
BRAF and PIK3CA were performed on DNA from confirmed malignant tissue using commercially available kits. Loss
of PTEN and EGFR was assessed by immunohistochemistry.
Results: DNA was available in 94 patients. The frequency of KRAS, BRAF and PIK3CA mutations were 44%, 3% and
14%, respectively. All were non-responders. EGF receptor status by IHC and loss of PTEN failed to show any clinical
importance. KRAS and BRAF were mutually exclusive. Supplementing KRAS analysis with BRAF and PIK3CA
indentified additional 11% of non-responders. Patient with any mutation had a high risk of early progression,
whereas triple-negative status implied a response rate (RR) of 41% (p < 0.001), a disease control (DC) rate of 73%
(p < 001), and a significantly higher PFS of 7.7(5.1-8.6 95%CI) versus 2.3 months (2.1-3.695%CI) (p < 0.000).
Conclusion: Triple-negative status implied a clear benefit from treatment, and we suggest that patient selection
for third-line combination therapy with cetuximab/irinotecan could be based on triple mutational testing.
Background
Selection of patients for epidermal growth factor recep-
tor targeted monoclonal antibodies (MoAbs) based on
tumour KRAS analysis is a major step towards tailored
treatment in metastatic colorectal cancer. An increasing
amount of data has demonstrated that response to anti-
EGFR MoAbs is confined to patients with KRAS wild
type tumour [1-4]. Patients harbouring KRAS mutations
are not likely to benefit from these drugs and KRAS
testing is now recommended in this setting [5]. Still, a
major fraction of the KRAS wild-type patients are non-
responders, and may not benefit from treatment. The
anti-EGFR MoAbs imply a substantial degree of toxicity,
and investigations of supplementary predictive factors
are therefore highly relevant.
Downstream signalling by the RAS-RAF-MAPK path-
way is normally very tightly regulated. However, muta-
tions in the KRAS gene render the KRAS protein
constitutively active regardless of extracellular EGFR
inhibition [2]. Mutations in the genes coding for the
other members of the RAS-RAF-MAPK pathway have
been identified and may theoretically determine primary
resistance to EGFR inhibition in a similar matter [4,6].
This has been suggested by cell line studies and clinical
data presented by Nicolantonio et al who investigated
BRAF and KRAS status in 113 patients treated with
panitumumab or cetuximab [4,7,7]. Oncogenic activa-
tion of BRAF is present in approximately 8-10% of col-
orectal tumours and seems mutually exclusive from
KRAS mutations according to the literature. A hotspot
in colon 600 accounts for the majority of BRAF muta-
tions. However, the relatively low frequency of BRAS
mutations detected may be due to poor sensitivity assays
(e.g direct sequencing) similar to previously published
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cal aspects warrant investigation, including development
of high-sensitive methods.
Activation of the phosphatidylinositol 3-kinase (PI3K/
AKT) pathway is another central mechanism of tumour
cell regulation. The PI3K/AKT pathway is critical for
development of malignant tumours, constitutes a relevant
target for anticancer therapy and regulates the central
mTOR pathway, which is influenced by chemotherapeu-
tics and new biological agents [6,9,10]. PI3K stimulates
the phosphorylation of AKT by interaction with phos-
phatidylinositol-3-phosphate in the cell membrane. A
catalytic subunit of the PI3K is encoded by the PIK3CA
gene, which harbour activating mutations in 10-30% of
colorectal tumours according to the literature [6,11-13].
The PI3K/AKT pathway promotes cellular proliferation,
invasion, cell survival and neo-angiogenesis [10,14], and
PI3K-initiated signalling is normally inhibited by the
phosphatase and tensin homolog (PTEN) gene located
on chromosome ten. Consequently, PIK3CA mutations
and/or loss of PTEN may render malignant cells resistant
to EGFR inhibition as described in preclinical studies
[15]. This has also been suggested in a recently published
clinical trial including 110 patients with metastatic color-
ectal cancer. A clear association was demonstrated
between loss of PTEN/PIK3CA mutations and response
to different regimes of EGFR-tageted MoAbs. Further-
more, an independent prognostic value regarding pro-
gression free survival was reported by multivariate
analysis [13,16].
The EGF receptor expression by IHC has been dis-
charged as predictive marker for response, but the pre-
vious data has assessed the receptor status in full
populations and not in relation to the mutational status.
Just recently a small study has suggested a reconsidera-
tion of this aspect by demonstrating a positive predictive
value of adding the EGFR expression to KRAS muta-
tional status. The study included 95 patients treated
with FOLFIRI or FOLFOX+ cetuximab treatment, and
EGFR expression was investigated by IHC and gene
expression on primary tumour tissue [17]. The relevance
of performing EGF receptor analysis in third-line treat-
ment for KRAS wild-type disease remains to be
determined.
As supplement to KRAS analysis, BRAF and PIK3CA
mutations as well as loss of PTEN and EGFR expression
may account for additional non-responders to EGFR tar-
geted MoAbs. The few previously published studies have
combined data from patients treated with different
EGFR targeted antibodies as mono- or combination-
therapy in first, second and third-line settings. Various
methods for mutational testing have been used. The aim
of the present study was to investigate the clinical value
of triple KRAS, BRAF and PIK3CA mutational testing by
commercially available kits combined with immunohis-
tochemical testing of EGFR and PTEN loss in a material
of patients with metastatic colorectal cancer. All patients
were treated in a single institution with uniform combi-
nation therapy cetuximab-irinotecan (CETIRI).
Methods
Patient material
We included 107 heavily pre-treated patients with meta-
static colorectal cancer, previously exposed to fluoropyr-
imidine, irinotecan and oxaliplatin containing regimes
and admitted for third line treatment with cetuximab
and irinotecan. Clinical eligibility criteria were; Histolo-
gically confirmed mCRC (adenocarcinomas) refractory
to prior chemotherapy, age over 18 years, ECOG perfor-
mance status ≤ 2, adequate organ function, and measur-
able disease according to the Response Evaluation
Criteria in Solid Tumours (RECIST) [18]. Patients were
treated with a combination of irinotecan (350 mg/m
2
q3w) and cetuximab (400 mg/m
2 loading dose followed
by weekly 250 mg/m
2). Response was classified accord-
ing to RECIST. Treatment was terminated upon pro-
gression or in 6 patients after prolonged duration of
treatment. Paraffin-embedded primary tumours and/or
corresponding metastasis (in one patient only metastatic
tissue was available and therefore used for testing) were
collected from referring departments of pathological.
The study was conducted in accordance with the Danish
law after approval by the Regional Ethics Committee.
Oral and written consent was obtained from all patients.
DNA purification and KRAS, BRAF and PIK3CA mutational
analysis
D N Aw a se x t r a c t e df r o mf o r m a l i n - f i x e dp a r a f f i n -
embedded tissue using QIAamp DNA Mini Kit (QIA-
GEN) after histological confirmation of viable tumour
cells on HE stained slides. Mutant KRAS, BRAF and
PIK3CA were determined by pre-developed kits identify-
ing seven somatic KRAS mutations (G12A, G12R,
G12D, G12C, G12S, G12V and G13D), one BRAF muta-
tion (E600V) and 4 PIK3CA mutations (E542K, E545K,
E545D and H1047R) (DxS Ltd, Manchester, United
Kingdom). Allele-specific real-time quantitative PCR
(qPCR) was performed on an ABI7900HT Sequence
Detection System (Applied Biosystems, Foster City, CA)
according to manufacturer’s recommendation.
PTEN and EGFR immunohistochemistry
Immunohistochmical stainings were performed on 4 μm
thick sections. Briefly, after deparaffination in graded
alcohol solutions antigen retrieval was performed by
microwaving in Tris-EGTA buffer, pH 9,0. Subse-
quently, the slides were incubated with antibody against
PTEN (Dako, clone 6H2.1, dilution 1:400), and EGFR
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tion 1:75). The reactions were visualized with Super
Sensitive (BioGenex) and ENVISION (DAKO Cytoma-
tion-DK) with DAB, followed by counterstaining with
haematoxylin. Staining was performed manually.
The PTEN reaction was considered negative if more
than 50% of the tumor cells were negative or weakly
stained, compared to the adjacent stromal cells which
served as internal control.
EGFR positivity was defined according to DAKO
guidelines, any membrane staining above background
level was considered positive. Tumours were graded
with regard to intensity and amount of membrane stain-
ing. A score of staining intensity was assigned as follows:
1+ = weak, 2+ = moderate and 3+ = strong membrane
staining. The tumour was defined positive if ≥1% of the
cells had membranous staining for EGFR according to
the DAKO guidelines. A tumour with less than 1% posi-
tive cells was considered EGFR-negative. The score was
defined according to the percentage of positively stained
tumour cells as follows: 0 = less than 1%, 1 = 1-10%, 2
= 10-25%, 3 = 25-50%, 4 = > 50%.
Evaluation was independently performed by two inves-
tigators (KGS and JL/SKF). The inter- and intra observer
reproducibility of assessments of the IHC staining was
tested by calculating Cohen’s kappa and showed excel-
lent agreement (data not shown).
Statistics
The association between mutational status and objective
response rates, baseline characteristics and skin-toxicity
rates was determined by two-tailed Fisher`s exact test.
Patients who ended treatment before the first objective
tumour evaluating were included in analysis as non-
responders, except from patients experiencing anaphy-
lactic reaction during the first treatment dose. Survival
analyses were performed according to the Kaplan-Meier
method and survival curves compared by the log-rank
test. Progression free survival was defined as time from
start of treatment until documented tumour progression
or death. Overall survival was calculated from date of
first treatment until death of any course. All-p-values
were two-sided and considered significant if p ≤ 0.05.
Statistics were carried out using the NCSS statistical
software 2007 v.07.1.5 (NCSS Statistical Software, Utah
84037, USA, http://www.ncss.com).
Results
One-hundred and seven patients were prospectively
included in the study, and 103 patients completed at
least one cycle of combination therapy. The median
number of cycles was 6 (range 1-18). Eighty-six patients
were evaluable for response according to RECIST.
Twenty-one patients received less than 3 cycles and
were consequently not evaluated by radiological exami-
nation according to study schedule. Study treatment was
terminated in three cases because of grade 3-4 allergic
reactions during the first infusion. One patient withdrew
consent after the first dose for psychological reasons.
Furthermore 8 patients showed clinical progression and
stopped treatment after one cycle and 10 after the sec-
ond cycle of treatment. Additional patient characteristics
are presented in table 1.
The overall response rate (RR) was 19% (20/103) and
34% (35/103) achieved stable disease. Eighty-three
patients (81%) were non-responders as defined by pro-
gressive disease (PD) + stable disease (SD) and included
17 patients who showed progression within the first 3
cycles. Skin toxicity data were available in 84% of the
patients and graded according to CTC criteria. At the
time of analysis 10 patients were still alive, including 3
patients with stable disease. The median observation
time was 7.7 months (range 0.8-31). The median pro-
gression free survival of the 103 patients who completed
the first cycle was 3.9 months (2.6-4.7 95% CI) and the
median overall survival 7.3 months (5.8-9.9 95%CI).
EGFR expression
Sixty-eight tumours were available for EGFR staining.
Forty-seven percent were negative, whereas 36 (53%)
tumours showed a positive staining including 17 with
intensity 2 or greater. EGFR IHC status was not asso-
ciated with clinicopathological parameters, response or
survival in the full cohort (table 2) or in selective analy-
sis in the KRAS wild type patients (data not shown).
Mutational status
In 13 patients we failed to receive tumour tissue for
mutational testing and consequently mutational status
was assessed in a total of 94 patients. KRAS mutations
were detected in 41 patients (44%), as presented in table
2. Only 3 patients had BRAF mutations and these were
all KRAS wt tumours as show in table 3. A similar
mutual exclusiveness was not revealed by the PIK3CA
analysis, where 7, 5 and 1 patient harboured mutations
located in codon E542, E545 and E1047, respectively.
Concomitant PIK3CA and KRAS mutations were
observed in 8 patients. Loss of PTEN as defined by less
than 50% of tumour cells positive for PTEN immunos-
taining was detected in 13 of the 73 (18%) tumours
available for PTEN staining.
Mutational profiling and clinico-pathologic characteristics
No significant association was revealed between KRAS,
BRAF, PIK3CA/PTEN mutational status/loss of staining
and age, gender, tumour location or any of the pre-
treatment characteristics listed in table 1 (Data not
shown).
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outcome
Clinical outcome and mutational status are presented in
table 2 and revealed response rates between 20% and
37% in patients tested negative for either mutations.
All three patients with BRAF mutation were non
responders and furthermore there was a lower DC rate,
median PFS and OS in patients carrying this mutation.
The statistical analysis on BRAF mutations did not
reach significance, which was most probably due to the
low number (3) of patients with BRAF mutations
detected.
The PIK3CA mutational analysis revealed a signifi-
cantly clinical benefit in terms of response, disease con-
trol, as well as PFS and overall survival in patients with
PIK3CA wild type status. Only this mutation reached
statistical significance in univariate overall survival ana-
lysis. Patients with PIK3CA mutations achieved a med-
ian PFS of 2.3 month and a median OS of 5.8 months
compared to 4.6 and 9.2 months, respectively, in
patients who did not carry these mutations.
Only one of the 13 patients with loss of PTEN (8%)
achieved response compared to 29% of patients with
normal PTEN expression. The difference was not signifi-
cant, and even less pronounced with respect to disease
control rates in the two groups. Similarly, there was no
significant difference in PFS or OS between the two
groups. Consequently, this marker was excluded for
further analysis, and the KRAS, BRAF and PIK3CA
mutations were selected for combined mutational
analysis.
Triple mutational status and clinical outcome
All the 49 patients with KRAS, BRAF or/and PIK3CA
mutations were non-responders, and consequently the
response rate in patients with triple negative mutational
test vas 42% p < 0.0001). Furthermore, these patients
achieved a disease control rate of 73% (compared to
41% in the mutational group, p = 0.001) and the median
progression free and overall survival rates were
increased to 7.7 and 10.2 months, respectively in this
group of patients. Notably, 22% of the patients with one
or more mutations showed early progressed before the
third cycle compared to 7% in the triple negative group
(p = 0.03). Kaplan-Meier plots and univariate survival
analysis are presented in figure 1.
Discussion
KRAS mutations only accounts for 30-40% of the non-
responders to EGFR targeted MoAbs in colorectal can-
cer. Considering the fact that these agents are now
established treatment options in metastatic colorectal
cancer and widely used, identification of genetic deter-
minants of primary resistance in KRAS wild type tumour
Table 1 Patient characteristics
Characteristic Patients (n = 107)
No. (%)
Age, Years
Median 62
Range 38-82
Gender
Female 49 (46)
Male 58 (54)
ECOG performance status
0 55 (51)
1 42 (39)
2 10 (10)
No. of prior chemotherapy regimes for
metastatic disease
2 79 (74)
3 27 (25)
NA 1 (1)
Primary surgery for CRC
Yes 97 (91)
No 9 (8)
NA 1 (1)
Pre-operative chemoradiation
Yes 17 (16)
No 88 (82)
NA 2 (2)
Anatomic site
Colon 40 (37)
Rectosignoideum 36 (34)
Rectum 39 (36)
NA 3 (3)
No. of metastatic sites
1-2 48 (45)
3-5 57 (53)
NA 1 (1)
No of cycles
Median 6
Range 1-18
Best response
PR 20 (19)
SD 35 (33)
PD 31 (29)
Clinical progression* 17 (16)
NA 4 (4)
Worst Toxicity/Rash grade
0 15 (14)
1 41 (39)
2 19 (18)
3 11 (13)
NA 25 (23)
Legend; NA (not assessed), PR, partial response; SD, stable disease, PD
progressive disease, * clinical progression (at investigators discretion) in
patients who were treated with less than 3 series and consequently not
evaluated according to RECIST.
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study investigated relevant mutations related to down-
stream signalling, which have shown promising results
in a few studies.
The purpose of the EGFR analysis was to assess a pos-
s i b l ep r e d i c t i v ev a l u ei nK R AS wild type patients only,
since most previous data have failed to distinguish
between KRAS wt and mutated patients. The EGFR
expression by immunohistochemistry was evaluated in
68 patients and did not provide any additional predictive
or prognostic value to mutational testing, as suggested
by Yen et al [17]. Our findings are supported by the
results from a phase III study which investigated che-
motherapy and bevasizumab with or without cetuximab
(Phase III CAIRO2) as first line treatment for mCRC.
EGFR IHC was not a predictive marker in this setting of
oxaliplatin based first line regime [19]. Thus, EGFR test-
ing prior to treatment has limited utility, even when
accounting for KRAS mutational status.
We confirm the previous literature on KRAS mutational
analysis regarding association to non-responsiveness and
PFS, but not OS. Of note, the present frequency of 44%
mutated tumours is marginally higher than previously pre-
sented [3,4].
All BRAF mutant tumours were non-responders and
all mutually exclusive from mutated KRAS. The overall
BRAF V600E mutational rate was 3% compared to
approximately 8-10% reported in the literature
[2,4,7,12,20-23]. The low frequency could be a natural
statistical variation (The 95% CIs of 3/100 are 0.6-8.5).
Also, the frequency of BRAF mutations is expected to
vary between different studies according to criteria for
patient selection, line of treatment, PS, limited or
advanced disease or further characteristics like geo-
graphic variation and microsatellite status amongst
others. Furthermore, heterogeneity of BRAF mutational
status in tumour compared to metastasis may compli-
cate results. The low frequency of BRAF mutations may
also rely on methodological aspects. The method used
in our study was therefore validated with a sensitive in-
house PCR method a well as direct sequencing, and the
results were in complete agreement (data not shown).
Table 2 Outcome according to marker status
Response Disease Median PFS Median OS
Rate Control Rate months (95% CI) months (95% CI)
Total (n = 94) 20% 56% 4.2 (2.8-5.1) 8.6 (5.9-10.4)
KRAS
Mutation (n = 41) 0% 45% 2.8 (2.2-4.1) 6.5 (4.8-9.8)
wild type (n = 53) 37% 65% 6.5 (3.5-8.4) 9,9 (6.0-12.2)
p < 0.000 p > 0.05 p = 0.0007 p > 0.05
BRAF
Mutation (n = 3) O% 33% 2.1 (1.9-8.5) 4.5 (3.5-25.7)
Wild type (n = 90) 20% 56% 4.2 (2.8-5.1) 8.6 (5.9-10.4)
p > 0.05 p > 0.05 p > 0.05 p > 0.05
PIK3CA
Mutation (n = 13) 0% 15% 2.2 (2.1-2.3) 3.5 (3.0-4.7)
Wild type (n = 81) 23% 63% 4.6 (3.5-6.2) 9.2 (6.6-11.1)
p = 0.053 p = 0.001 p = 0.0003 p = 0.003
PTEN IHC
Loss of PTEN (n = 13) 8% 46% 3.3 (2.1-6.3) 5.9 (3.6-10.9)
Normal expression (n = 59) 23% 57% 4.4 (2.8-6.2) 9.2 (6.9-11.1)
p > 0.05 p > 0.05 p > 0.05 p > 0.05
EGFR IHC
Positive staining (n = 36) 25% 61% 4.3 (2.2-5.7) 9.0 (6.1 -10.9)
Negative staining (n = 32) 22% 43% 2.8 (2.1-6.9) 8.6 (3.5 - 11.1)
p > 0.05 p > 0.05 p > 0.05 p > 0.05
Triple mutation
*mutation (n = 49) 0% 40% 2.3 (2.1-3.6) 5.8 (4.5-9.2)
Negative (n = 45) 41% 73% 7.7 (5.1-8.6) 10.2 (7.1-12.5)
p < 0.0000 p = 0.001 p < 0.000 p > 0.05
*Any of the three mutations detected in primary tumour or metastatic tissue.
# In a few cases DNA was not available for testing of all three mutations.
Response and disease control rates calculated by chi-square test.
Progression free survival (PFS) and overall survival (OS) calculated by log-rank test.
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responders in this study, and is consequently regarded
as clinical relevant for further selection, as confirmed by
a recent pooled analysis of a larger sample size [4].
The PIK3/PTEN pathway is crucial to EGFR signalling
and PTEN evaluation is very central to regulation [10].
Unfortunately the PTEN gene is large and mutations
result in a loss of function and therefore not located in
hotspots. Consequently, loss of PTEN protein evaluated
by immunohistochemistry is a more attractive approach
to mutational detection than a complete DNA sequen-
cing. However, the value of PTEN IHC has been debated.
In contrast to the studies by Perroni et al and Sartori
Bianchi et al [12,13], two other studies failed to demon-
strate a significant impact on response by the PTEN
assessment [24,25]. We aimed to investigate the predic-
tive and prognostic influence of this marker but found it
limited in the present material. Another recent study sug-
gested that PTEN IHC was a potential predictive marker
when stained on metastatic but not on primary tissue as
used in the present study [16]. Methodological difficulties
in demonstrating a lack of expression by a semi quantita-
tive method could be an obvious explanation for these
findings. Sequencing of the PTEN gene may contribute
further to the knowledge. It is however, a complicated
and demanding method, and the analysis is probably not
justified for use as a clinical tool.
The PIK3CA mutations were detected in 13% percent
of available patients, which is in agreement with the pre-
vious literature [4,6,10,11,13,26]. A few publications have
assessed the clinical impact of these mutations in EGFR
targeted therapies. Perrone and colleagues described a
significant impact on response and PFS by PIK3CA/
PTEN mutations in a small study of 32 patients [12],
and Sartori-Bianchi et al presented a significant PFS and
OS survival benefit in non-mutated tumours, and sug-
gested that these mutations may be a rational supple-
ment to KRAS mutational testing with potential for
clinical application [13]. However, these results are con-
tradicted by a recent retrospectively study of 200
patients with mCRC, which revealed that 5 of 22
patients carrying PIK3CA mutations responded to treat-
ment, and it was concluded that this mutations do not
play a major role in primary resistance to EGFR MoAbs
Table 3 Distribution of the different mutations
Patient KRAS mutations BRAF mutations PIK3CA mutations
1 12ALA wt Wt
2 12ALA wt Wt
3 12ALA wt Wt
4 12ALA wt Wt
5 12ARG wt Wt
6 12ARG wt Wt
7 12ARG wt Wt
8 12ASP wt E542K
9 12ASP wt E542K
10 12ASP wt E545K/D**
11 12ASP wt E545K/D
12 12ASP wt E545K/D
13 12ASP wt Wt
14 12ASP wt Wt
15 12ASP wt Wt
16 12ASP wt Wt
17 12ASP wt Wt
18 12ASP wt Wt
19 12ASP wt Wt
20 12ASP wt Wt
21 12ASP wt Wt
22 12ASP wt Wt
23 Mut* NA NA
24 12CYS wt E542K
25 12CYS wt Wt
26 12CYS wt Wt
27 12SER wt Wt
28 12SER wt Wt
29 12VAL wt E542K
30 12VAL wt H1047R
31 12VAL wt Wt
32 12VAL wt Wt
33 12VAL wt Wt
34 12VAL wt Wt
35 12VAL wt Wt
36 13ASP wt Wt
37 13ASP wt Wt
38 13ASP wt Wt
39 13ASP wt Wt
40 13ASP wt Wt
41 13CYS wt Wt
42 wt E600 Wt
43 wt E600 Wt
44 wt E600 Wt
45 wt wt E542K
46 wt wt E542K
Table 3 Distribution of the different mutations
(Continued)
47 wt wt E542K
48 wt wt E545K/D
49 wt wt E545K/D
*KRAS mutational status assessed in external institution, but not specified.
**The DxS assay does not discriminate between the E545K and E545D
mutation.
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PIK3CA mutations was revealed. Consequently, the
PIK3CA analysis was not suggested as a single marker
of response. The study was based on a non-homoge-
neous patients material treated according to 4 different
clinical trials with either monotherapy cetuximab or
combination therapy, and is therefore not comparable to
our patient material. We detected a similarly substantial
overlapping between the KRAS and PIK3CA mutations,
but all PIK3CA mutated tumours in the present study
were non-responders. A recent pooled analysis included
data from 1022 patients with mCRC who were treated
with EGFR Moabs (according to a variety of treatment
regime and lines. The study investigated KRAS, NRAS
and BRAF together with different PIK3CA mutations and
has confirmed our result, but also suggested a significant
different outcome according to the different type of
PIK3CA mutations [4]. In the present study all patients
with PIK3CA mutations were non-responders, and we
were consequently unable to contribute to this aspect.
The sample size of the present study did not allow for
comparison of methodological aspects regarding sensi-
tivity for BRAF/PIK3CA mutations, or analysis of poten-
tial clinical differences according to the specific
locations of the KRAS mutations [4,16]. These aspects
will need assessment in larger studies. The same applies
to development of assays for detection of less frequent
KRAS, PIK3CA and BRAF mutations and the clinical
implication of these. However, this study included a
homogeneous group of patients who received identical
treatment dose and schedule in a single institution, in
comparison to the majority of recent studies. The
observation period allowed for data collection on pro-
gression and survival, and revealed a large number of
events (97) for survival analysis. Only four patients had
not progressed at time of analysis and consequently the
strength of statistical analysis on multiple parameters
appears acceptable. The median progression free survi-
val in triple negative patients was 7.7 months and held a
median overall survival of 10.2 months, indicating a
clear benefit from treatment in this group of patients
compared to those with one or more mutations. Despite
the present limitations, by adding the BRAF and
PIK3CA mutational analysis to KRAS testing we identi-
fied additional 11% of the non-responders.
Conclusion
In conclusion, it is a major challenge to identify patients
with a considerable risk of unnecessary toxic side effects
and limited benefit from treatment. The present data
suggest that patients harbouring any of the three muta-
tions have a very low chance of response and a high risk
of early progression before the third cycle of treatment.
Furthermore, the triple negative patients achieved a sig-
nificantly higher disease control rate which translates
into a marked increase of progression free survival rate
compared to patients with any of the three mutations.
Consequently, we suggest that patient selection for
third-line combination therapy with EGFR monoclonal
antibodies and irinotecan could be based on triple muta-
tional testing.
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Figure 1 Progression free survival (A) and overall survival (B) in triple negative patients and patients with any mutations detected.
The median progression free survival was significantly higher in patients with triple negative mutational status (Red: 7.7 months (5.1-8.6, 95%CI))
compared to patients with one or more mutations (Blue: 2.3 months (2.1-3.6, 95% CI) P < 0.000). The HR was 2.24 (1.45-3.47 95% CI). The median
OS was significantly higher in patients with triple negative mutational status (Red: 10.2 months (7.1-12.5, 95%CI)) compared to patients with one
or more mutations (Blue: 5.8 months (4.5-9.2, 95% CI) p = 0.31). The HR was 1.23 (0.81-1.89 95% CI).
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